Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Szymon Zmorzynski

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Genes|March 28, 2024
In Vitro Low-Bortezomib Doses Induce Apoptosis and Independently Decrease the Activities of Glutathione S-Transferase and Glutathione Peroxidase in Multiple Myeloma, Taking into Account the <i>GSTT1</i> and <i>GSTM1</i> Gene VariantsSzymon Zmorzynski, Sylwia Popek-Marciniec, Beata Biernacka, et al.
Frontiers in Oncology|March 21, 2025
Associations of ANGPT2 expression and its variants (rs1868554 and rs7825407) with multiple myeloma risk and outcomeSylwia Popek-Marciniec, Wojciech Styk, Sylwia Chocholska, et al.
Peerj|May 2, 2025
Effects of bortezomib on intracellular antioxidant and apoptosis in HepG2cellsGrażyna Świderska-Kołacz, Magdalena Madej, Szymon Zmorzynski, et al.
Molecules (Basel, Switzerland)|September 13, 2025
The Impact of Proinflammatory M1 Macrophages on the Proliferation and Expression of Cyclin E2, Mitogen-Activated Protein Kinases 4 and 7 in Hepatocytes Isolated from a Diethylnitrosamine-Induced Hepatocellular Carcinoma Rat ModelMarta Wójcik, Luisa Pozzo, Andrea Vornoli, et al.
Journal of Clinical Medicine|March 29, 2023
The Relationship of <i>CCL5</i> and <i>CCR1</i> Variants with Response Rate and Survival Taking into Account Thalidomide/Bortezomib Treatment in Patients with Multiple MyelomaSylwia Popek-Marciniec, Wojciech Styk, Magdalena Wojcierowska-Litwin, et al.
Cancers|October 14, 2023
Association of Chromosome 17 Aneuploidy, <i>TP53</i> Deletion, Expression and Its rs1042522 Variant with Multiple Myeloma Risk and Response to Thalidomide/Bortezomib TreatmentSylwia Popek-Marciniec, Wojciech Styk, Magdalena Wojcierowska-Litwin, et al.
Frontiers in Oncology|February 22, 2019
<i>ACE</i> Insertion/Deletion Polymorphism (rs4646994) Is Associated With the Increased Risk of Multiple MyelomaSzymon Zmorzynski, Aneta Szudy-Szczyrek, Sylwia Popek-Marciniec, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Genes|March 28, 2024
In Vitro Low-Bortezomib Doses Induce Apoptosis and Independently Decrease the Activities of Glutathione S-Transferase and Glutathione Peroxidase in Multiple Myeloma, Taking into Account the <i>GSTT1</i> and <i>GSTM1</i> Gene VariantsSzymon Zmorzynski, Sylwia Popek-Marciniec, Beata Biernacka, et al.
Frontiers in Oncology|March 21, 2025
Associations of ANGPT2 expression and its variants (rs1868554 and rs7825407) with multiple myeloma risk and outcomeSylwia Popek-Marciniec, Wojciech Styk, Sylwia Chocholska, et al.
Peerj|May 2, 2025
Effects of bortezomib on intracellular antioxidant and apoptosis in HepG2cellsGrażyna Świderska-Kołacz, Magdalena Madej, Szymon Zmorzynski, et al.
Molecules (Basel, Switzerland)|September 13, 2025
The Impact of Proinflammatory M1 Macrophages on the Proliferation and Expression of Cyclin E2, Mitogen-Activated Protein Kinases 4 and 7 in Hepatocytes Isolated from a Diethylnitrosamine-Induced Hepatocellular Carcinoma Rat ModelMarta Wójcik, Luisa Pozzo, Andrea Vornoli, et al.
Journal of Clinical Medicine|March 29, 2023
The Relationship of <i>CCL5</i> and <i>CCR1</i> Variants with Response Rate and Survival Taking into Account Thalidomide/Bortezomib Treatment in Patients with Multiple MyelomaSylwia Popek-Marciniec, Wojciech Styk, Magdalena Wojcierowska-Litwin, et al.
Cancers|October 14, 2023
Association of Chromosome 17 Aneuploidy, <i>TP53</i> Deletion, Expression and Its rs1042522 Variant with Multiple Myeloma Risk and Response to Thalidomide/Bortezomib TreatmentSylwia Popek-Marciniec, Wojciech Styk, Magdalena Wojcierowska-Litwin, et al.
Frontiers in Oncology|February 22, 2019
<i>ACE</i> Insertion/Deletion Polymorphism (rs4646994) Is Associated With the Increased Risk of Multiple MyelomaSzymon Zmorzynski, Aneta Szudy-Szczyrek, Sylwia Popek-Marciniec, et al.
Pageof 2